
    
      A once-daily immunosuppressant regimen comprising of Envarsus-everolimus-prednisone will have
      6-month treatment failure rates that are non-inferior to the twice-daily regimen of
      Envarsus-mycophenolate mofetil-prednisone and will have improved patient-reported adherence.
    
  